IBL-302

Product Specifications

CAS Number

1414455-21-2

Target

PI3K|||Akt|||mTOR|||Pim

Related Pathways

Cytoskeletal Signaling|||Chromatin/Epigenetic|||PI3K/Akt/mTOR signaling|||JAK/STAT signaling

Bioactivity

IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].

Smiles

CC=1C2=C3C(C=4SC(=CC4)CNC(=O)C=5C=C(S(=O)(=O)NC6=CC(C1S3)=CN=C6OC)C=CC5F)=NC=N2

Molecular Formula

C25H18FN5O4S3

Molecular Weight

567.64

Shipping Conditions

Cool pack

Storage Temperature

-20°C

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

395659 200 µL

TRIM16 discontinued

Ask

View Details

sc-526971 1 Kit

Cytokeratin 1 (4D12B3) : m-IgG Fc BP-HRP Bundle

Ask

View Details

NBP2-22260JF646 0.1 mL

Rabbit Polyclonal CARHSP1 Antibody [Janelia Fluor 646]

Ask

View Details